Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 106,900 shares, a decline of 22.0% from the January 31st total of 137,000 shares. Currently, 3.9% of the shares of the company are short sold. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PALI shares. Brookline Capital Management started coverage on Palisade Bio in a report on Wednesday, November 20th. They set a “buy” rating and a $38.00 price objective for the company. Maxim Group cut their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Palisade Bio stock. Cetera Investment Advisers acquired a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,006 shares of the company’s stock, valued at approximately $116,000. Cetera Investment Advisers owned approximately 2.53% of Palisade Bio at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Price Performance

Shares of PALI opened at $0.83 on Tuesday. Palisade Bio has a one year low of $0.80 and a one year high of $9.65. The company has a market cap of $2.29 million, a P/E ratio of -0.06 and a beta of 1.43. The firm has a 50 day simple moving average of $1.42 and a two-hundred day simple moving average of $2.46.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.